Best Healthcare Stocks to Buy in 2026

Biogen and Novo Nordisk both have positive catalysts from new product forms and label expansions, with Biogen’s Leqembi subcutaneous filing delayed but still supported by more than 50 regulatory approvals for IV dosing. Biogen Q1 revenue rose 2% to $2.5 billion, EPS climbed 31% to $2.15, and Leqembi sales jumped 74% to $168 million; Novo Nordisk posted Q1 revenue of 96.8 billion DKK, up 24%, with operating profit up 54% to 59.6 billion DKK. The article favors Novo Nordisk as the better buy due to stronger growth, acquisition-driven diversification, and a sub-11x earnings valuation.

Analysis

The setup is less about headline drug demand and more about whether each company can convert a single-product catalyst into a broader re-rating. For BIIB, the meaningful second-order effect is channel friction: a subcutaneous autoinjector changes adoption economics for caregivers, home-health providers, and specialty pharmacies, so even a modest delay can defer the inflection by quarters rather than years. That matters because the market is likely underestimating how quickly convenience can expand persistence in a disease area with notoriously poor treatment adherence.

For NVO, the competitive issue is not whether it is growing, but whether growth is decelerating from scarcity-driven to execution-driven. The market may be over-penalizing the stock for Lilly’s advances while underappreciating that a lower multiple plus capital returns plus M&A creates a more durable compounding machine than a pure obesity trade. If GLP-1s keep winning label expansions, insurers will increasingly view them as a cost-offsetting platform, which can support broader utilization even if headline prescription growth normalizes.

The contrarian angle is that both names have option value the market has not fully capitalized, but for different reasons: BIIB on a product-form change that could unlock latent demand, NVO on internal funding capacity to buy duration. The bigger risk for BIIB is that the turnaround narrative becomes self-funding too early and the stock rerates before operating leverage is proven; the bigger risk for NVO is that expectations for perpetual category dominance leave no room for margin normalization or pricing pressure if competition broadens faster than label expansion offsets it.

Key Decisions for Investors

• Long NVO on 3-6 month horizon; use weakness into the high-10x earnings multiple as entry. Risk/reward favors owning the cash-generating leader with dividend support and self-funded pipeline/M&A optionality.
• Buy BIIB only as a catalyst trade, not a core hold: initiate on pullbacks ahead of regulatory clarity on subcutaneous Leqembi, with a 1-3 month time frame and tight stop if the review slips again. Upside is a convenience-driven re-rating; downside is delay fatigue.
• Pair trade: long NVO / short a basket of higher-multiple GLP-1 adjacencies or obesity beneficiaries. The spread is attractive if the market keeps rewarding durable cash flow over pure growth narratives.
• For BIIB, consider call spreads rather than stock if you expect approval within one quarter. That captures upside from a successful label expansion while limiting exposure to another timing miss.
• Fade overreaction in APLS and AKRO only selectively; treat them as secondary beneficiaries of the M&A bid for metabolic and rare-disease assets, but recognize that deal value may already be partially embedded.